RT Journal Article
SR Electronic
T1 The differential immune responses to COVID-19 in peripheral and lung revealed by single-cell RNA sequencing
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.08.15.20175638
DO 10.1101/2020.08.15.20175638
A1 Gang Xu
A1 Furong Qi
A1 Hanjie Li
A1 Qianting Yang
A1 Haiyan Wang
A1 Xin Wang
A1 Xiaoju Liu
A1 Juanjuan Zhao
A1 Xuejiao Liao
A1 Yang Liu
A1 Ido Amit
A1 Lei Liu
A1 Shuye Zhang
A1 Zheng Zhang
YR 2020
UL http://medrxiv.org/content/early/2020/08/17/2020.08.15.20175638.abstract
AB Understanding the mechanism that leads to immune dysfunction induced by SARS-CoV2 virus is crucial to develop treatment for severe COVID-19. Here, using single cell RNA-seq, we characterized the peripheral blood mononuclear cells (PBMC) from uninfected controls and COVID-19 patients, and cells in paired broncho-alveolar lavage fluid (BALF). We found a close association of decreased dendritic cells (DC) and increased monocytes resembling myeloid-derived suppressor cells (MDSC) which correlated with lymphopenia and inflammation in the blood of severe COVID-19 patients. Those MDSC-like monocytes were immune-paralyzed. In contrast, monocyte-macrophages in BALFs of COVID-19 patients produced massive amounts of cytokines and chemokines, but secreted little interferons. The frequencies of peripheral T cells and NK cells were significantly decreased in severe COVID-19 patients, especially for innate-like T and various CD8+ T cell subsets, compared to health controls. In contrast, the proportions of various activated CD4+ T cell subsets, including Th1, Th2 and Th17-like cells were increased and more clonally expanded in severe COVID-19 patients. Patients’ peripheral T cells showed no sign of exhaustion or augmented cell death, whereas T cells in BALFs produced higher levels of IFNG, TNF, CCL4 and CCL5 etc. Paired TCR tracking indicated abundant recruitment of peripheral T cells to the patients’ lung. Together, this study comprehensively depicts how the immune cell landscape is perturbed in severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno external fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted according to the ethical principles of the Declaration of Helsinki. Ethical approval was obtained from the Research Ethics Committee of Shenzhen Third People's Hospital (2020-207).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data used in this study, including scRNA-seq raw data, expression matrix and scTCR-seq contig annotation that support the findings of this study will be released via a material transfer agreement upon reasonable request.